1. The Nevro acquisition is subject to shareholder and regulatory approval, but Globus Medical expects the deal to close in the second quarter, CEO Dan Scavilla said as transcribed by Motley Fool.
2. Mr. Scavilla said the company expects Nevro to be accretive to earnings in the second year of operations.
3. The Nevro acquisition will allow Globus Medical to touch a $2 billion market space, Mr. Scavilla said. Nevro is known for its spine products and spinal cord stimulator technologies.
“We believe our high-frequency technology offers clinically superior solutions that can alter the standard of care for patients,” Mr. Scavilla said. “Nevro technology has potential beyond its current application to benefit our cranial enabling technology, next-generation spinal implants, data mining, and other areas of our business.”
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
